Kratom Lingo
Explained
Over 290 Terms to Help.
Scroll down
Over 290 Terms to Help
You Understand the
Science of Leaf Kratom.
Understanding the Scientific Language of Leaf Kratom Research. Navigating the expanding body of leaf kratom research can be challenging due to its complex and often interdisciplinary scientific terminology. This comprehensive guide has been meticulously developed to translate essential terms and concepts, empowering consumers, policymakers, and various stakeholders to better comprehend the intricate scientific underpinnings and the nuanced findings emerging from ongoing leaf kratom research.
Plant Biology & Chemistry
Alkaloids
Naturally occurring chemical compounds found in plants that typically contain nitrogen and have physiological effects on humans. Kratom contains over 40 different alkaloids that work together to produce its effects. These compounds are the plant’s natural defense mechanisms and often have bitter tastes.
Mitragynine
The most abundant alkaloid in kratom leaves, typically comprising 60-70% of the total alkaloid content. Mitragynine acts on multiple receptor systems including opioid, adrenergic, and serotonergic receptors. Its concentration varies based on growing conditions, harvest timing, and processing methods.
7-Hydroxymitragynine (7-OH)
A metabolite that forms when mitragynine breaks down, either through processing or in the human body. Found in very small amounts in dried kratom leaves (<0.05% by weight) but is significantly more potent than mitragynine. Products with artificially high 7-OH levels are considered synthetic derivatives.
Paynantheine
A major alkaloid in kratom that acts as an antagonist at opioid receptors, potentially contributing to kratom’s unique safety profile by counteracting some opioid-like effects. Typically comprises 7-10% of total alkaloid content in fresh leaves.
Speciociliatine
Another major kratom alkaloid that, like paynantheine, acts as an opioid receptor antagonist and may contribute to the overall balance of kratom’s effects. Often found in concentrations of 8-12% of total alkaloids.
Speciogynine
A kratom alkaloid that demonstrates both agonist and antagonist properties at different receptors, contributing to the complex pharmacological profile of whole-leaf kratom. Typically represents 6-8% of total alkaloid content.
Mitraciliatine
A minor alkaloid found in kratom leaves that contributes to the overall alkaloid profile. While present in smaller quantities, it may play a role in the entourage effect of whole-leaf preparations.
Corynantheidine
A trace alkaloid in kratom that belongs to the same chemical family as other kratom compounds. Research on its specific effects is limited, but it contributes to the complex chemistry of whole-leaf kratom.
Isopaynantheine
Another minor alkaloid present in kratom leaves, related structurally to paynantheine but with potentially different pharmacological properties.
Rhynchophylline
An indole alkaloid found in some kratom varieties that may have cardiovascular and neurological effects, though research is limited.
Epicatechin
A flavonoid compound found in kratom leaves that has antioxidant properties and may contribute to the overall health effects of kratom consumption.
Total Alkaloid Content
The sum of all alkaloids present in a kratom sample, typically ranging from 0.5% to 1.5% in fresh leaves and 1.2% to 2.1% in dried leaf material.
Alkaloid Profile
The specific combination and concentrations of different alkaloids in a kratom sample, which can vary based on strain, growing conditions, and processing methods.
Mitragyna speciosa
The scientific name for the kratom tree, belonging to the coffee family (Rubiaceae). Native to Southeast Asia, particularly Thailand, Malaysia, Indonesia, and Myanmar.
Phenolic Compounds
Secondary metabolites in kratom that contribute to antioxidant activity and may have protective effects against cellular damage.
Tannins
Polyphenolic compounds in kratom that contribute to its bitter taste and astringent properties, potentially affecting absorption and bioavailability.
Pharmacology Terms
Receptor
Protein structures in cells that bind to specific chemicals and trigger biological responses. Kratom alkaloids interact with several receptor types including opioid, adrenergic, and serotonergic receptors.
Agonist
A substance that binds to and activates a receptor, triggering a biological response. Mitragynine is a partial agonist at mu-opioid receptors, producing effects but with less intensity than full agonists.
Antagonist
A substance that binds to a receptor but blocks or reduces its activity. Several kratom alkaloids act as opioid receptor antagonists, potentially providing a safety mechanism.
Partial Agonist
A substance that activates receptors but produces a weaker response than a full agonist, often providing a “ceiling effect” that may enhance safety by limiting maximum response.
Full Agonist
A substance that produces the maximum possible response from a receptor when sufficient amounts are present, unlike partial agonists which have limited maximum effects.
Inverse Agonist
A substance that binds to the same receptor as an agonist but produces the opposite effect, potentially relevant to some kratom alkaloids’ complex interactions.
Competitive Inhibition
When two substances compete for the same receptor binding site, potentially explaining how different kratom alkaloids may modulate each other’s effects.
Non-competitive Inhibition
When a substance binds to a different site on a receptor and changes its shape, affecting how other substances can bind and activate it.
Bioavailability
The proportion of a substance that enters circulation and can have an active effect when introduced into the body. Kratom’s bioavailability can be affected by food, individual metabolism, and product formulation.
First-Pass Metabolism
The process by which the liver metabolizes substances before they reach systemic circulation, significantly affecting the bioavailability of orally consumed kratom.
Half-life
The time required for the concentration of a substance in the body to reduce by half through metabolism and elimination. Mitragynine has a half-life of approximately 3.85 hours.
Clearance
The volume of plasma from which a substance is completely removed per unit time, indicating how efficiently the body eliminates the compound.
Volume of Distribution
A pharmacokinetic parameter that describes how extensively a substance distributes throughout body tissues versus remaining in blood plasma.
Pharmacokinetics
The study of how the body processes substances: absorption, distribution, metabolism, and elimination (ADME). Critical for understanding dosing and timing of kratom effects.
Pharmacodynamics
The study of how substances affect the body, including their mechanisms of action and dose-response relationships. Essential for understanding kratom’s therapeutic and adverse effects.
Dose-Response Relationship
The relationship between the amount of a substance administered and the magnitude of response produced, which can be linear or non-linear.
Therapeutic Window
The range of doses between the minimum effective dose and the dose that produces unacceptable adverse effects.
Ceiling Effect
A pharmacological phenomenon where increasing doses beyond a certain point do not produce proportionally greater effects, potentially contributing to kratom’s safety profile.
Cross-Tolerance
When tolerance to one substance results in tolerance to another similar substance, relevant to discussions of kratom and opioid interactions.
Allosteric Modulation
When a substance binds to a site other than the main binding site and changes the receptor’s response to other compounds, potentially explaining some complex kratom effects.
G-Protein Coupled Receptors (GPCRs)
A large family of receptors including opioid receptors that transduce signals from outside to inside cells, central to kratom’s mechanism of action.
Beta-Arrestin Pathway
A cellular signaling pathway associated with some adverse effects of opioids, which some kratom alkaloids may not activate as strongly.
Functional Selectivity
When a substance activates some but not all signaling pathways associated with a receptor, potentially explaining kratom’s unique effect profile.
Research & Study Terms
Single Ascending Dose (SAD) Study
A type of clinical trial that tests increasing doses of a substance in different groups to determine safety and tolerance levels. The FDA conducted a SAD study on kratom in 2024, finding it well-tolerated even at high doses.
Multiple Ascending Dose (MAD) Study
A clinical trial design that tests repeated doses over time to assess safety, tolerance, and potential accumulation effects of a substance.
Placebo-Controlled Study
A research design where some participants receive the active substance while others receive an inactive placebo, allowing researchers to isolate the effects of the substance being tested.
Double-Blind Study
A research method where neither participants nor researchers know who is receiving the active treatment versus placebo, reducing bias in results and improving reliability.
Randomized Controlled Trial (RCT)
The gold standard of clinical research where participants are randomly assigned to treatment or control groups, minimizing selection bias and confounding variables.
Crossover Study
A research design where each participant receives both the experimental treatment and control/placebo in different time periods, serving as their own control.
Cohort Study
An observational study that follows a group of people over time to assess outcomes, useful for studying long-term effects of kratom use.
Case-Control Study
A study that compares people with a specific outcome (cases) to those without it (controls) to identify potential risk factors or causes.
Cross-Sectional Study
A research design that examines data from a population at a single point in time, providing a snapshot of associations between variables.
Longitudinal Study
Research that follows the same participants over extended periods to track changes and developments over time.
Peer Review
The process by which scientific research is evaluated by independent experts before publication to ensure quality, validity, and significance of findings.
Systematic Review
A comprehensive analysis that uses explicit methods to identify, select, and critically evaluate relevant research on a specific question.
Meta-Analysis
A statistical analysis that combines results from multiple independent studies to provide stronger evidence and broader conclusions than individual studies.
Preclinical Studies
Research conducted in laboratory settings using cell cultures or animal models before human testing begins, essential for initial safety and efficacy assessment.
In Vitro Studies
Laboratory research conducted using cells or tissues outside their normal biological context, useful for understanding basic mechanisms of action.
In Vivo Studies
Research conducted in living organisms, including animal studies and human trials, providing more realistic physiological conditions.
Clinical Trials
Research studies conducted with human participants to test the safety and effectiveness of treatments or interventions, progressing through phases I-IV.
Phase I Clinical Trial
Early-stage human testing focused primarily on safety, dosage, and side effects, typically involving small numbers of participants.
Phase II Clinical Trial
Studies that test both safety and effectiveness in larger groups, often comparing the experimental treatment to existing treatments.
Phase III Clinical Trial
Large-scale studies comparing new treatments to current standard treatments, providing definitive evidence of effectiveness.
Phase IV Clinical Trial
Post-marketing surveillance studies conducted after approval to monitor long-term effects and rare adverse events in larger populations.
Observational Study
Research that observes participants without intervening or manipulating variables, useful for studying real-world patterns of kratom use.
Epidemiological Study
Research that studies the distribution and determinants of health-related events in populations, important for public health policy.
Case Report
A detailed description of an individual patient’s clinical course, useful for documenting rare events or unusual reactions.
Case Series
A collection of case reports describing similar clinical presentations, providing preliminary evidence of patterns or associations.
Safety & Regulation Terms
Good Manufacturing Practices (GMP)
Established guidelines that ensure products are consistently produced and controlled according to quality standards, covering facility design, equipment, personnel, and procedures.
Current Good Manufacturing Practices (cGMP)
Updated GMP standards that incorporate modern quality control methods and regulatory requirements for pharmaceutical and supplement manufacturing.
Certificate of Analysis (COA)
A document that provides detailed information about a product’s composition, including alkaloid content, contaminants, and quality testing results from third-party laboratories.
Third-Party Testing
Independent laboratory analysis conducted by facilities not affiliated with the manufacturer, providing unbiased assessment of product quality and safety.
Batch Testing
Quality control procedures that test each production batch of a product to ensure consistency and safety before release to market.
Adulterated
Products that contain harmful substances not declared on the label, have been contaminated during processing, or contain unsafe levels of contaminants.
Misbranded
Products with false or misleading labeling, including incorrect ingredient lists, unauthorized health claims, or inadequate warning statements.
New Dietary Ingredient (NDI)
According to FDA regulation, any dietary ingredient not sold in the U.S. before October 15, 1994, requiring additional safety documentation and FDA notification.
Old Dietary Ingredient (ODI)
Dietary ingredients with evidence of sale in the U.S. before October 15, 1994, which may have different regulatory requirements and grandfather protections.
Generally Recognized as Safe (GRAS)
FDA designation for substances that qualified experts consider safe under intended conditions of use, based on scientific data or long history of use.
Dietary Supplement Health and Education Act (DSHEA)
The 1994 federal law that established the regulatory framework for dietary supplements, including labeling requirements and FDA oversight responsibilities.
Food and Drug Administration (FDA)
The federal agency responsible for regulating food, drugs, and dietary supplements to ensure safety and proper labeling for consumers.
Heavy Metal Testing
Laboratory analysis to detect potentially harmful levels of lead, mercury, cadmium, and arsenic in kratom products.
Microbial Testing
Laboratory procedures to detect harmful bacteria, yeast, mold, and other microorganisms that could contaminate kratom products.
Pesticide Residue Testing
Analysis to detect residual agricultural chemicals that may remain on kratom leaves from cultivation practices.
Aflatoxin Testing
Specific testing for toxic compounds produced by certain molds that can contaminate agricultural products, including kratom.
Salmonella Testing
Microbiological testing to detect the presence of Salmonella bacteria, which can cause serious foodborne illness.
E. coli Testing
Laboratory analysis to detect pathogenic strains of E. coli bacteria that could pose health risks to consumers.
Yeast and Mold Count
Quantitative testing to determine levels of yeast and mold contamination, which must stay within acceptable limits for consumer safety.
Water Activity Testing
Measurement of moisture content that affects product stability and microbial growth potential during storage.
Label Claim Verification
Testing to confirm that products contain the amounts of active ingredients stated on their labels, ensuring accuracy and consumer trust.
Stability Testing
Studies that determine how long products maintain their quality, potency, and safety under various storage conditions.
Recall
The removal of products from the market when they pose safety risks or violate regulations, protecting consumers from potentially harmful products.
Adverse Event Reporting
The process by which manufacturers and consumers report negative health effects potentially associated with product use to regulatory authorities.
Product & Processing Terms
Whole Leaf Kratom
Kratom products made from dried, ground kratom leaves without chemical extraction or concentration of specific alkaloids, maintaining the natural alkaloid profile.
Kratom Powder
Finely ground dried kratom leaves, the most common form of whole-leaf kratom available to consumers, typically consumed mixed with liquids.
Kratom Capsules
Kratom powder enclosed in gelatin or vegetable-based capsules, providing a convenient and precise dosing method for consumers.
Extract
Products where alkaloids have been concentrated through chemical or physical processes, resulting in higher potency than whole leaf products and altered alkaloid ratios.
Full Spectrum Extract
Extraction methods that aim to preserve the complete range of alkaloids found in whole kratom leaves, maintaining the natural ratios.
Standardized Extract
Extracts processed to contain specific, consistent levels of particular alkaloids, often expressed as concentration ratios (e.g., 10:1, 50:1).
Isolate
Products containing predominantly one alkaloid that has been separated from the plant material, such as pure 7-hydroxymitragynine products that lack other kratom compounds.
Semi-Synthetic
Substances created by chemically modifying natural compounds, often through oxidation or other chemical processes that alter the original molecular structure.
Kratom Tea
Beverage prepared by steeping kratom leaves or powder in hot water, a traditional consumption method that may have different absorption characteristics.
Kratom Tincture
Liquid extracts made by soaking kratom in alcohol or other solvents to concentrate active compounds, typically more potent than powder.
Enhanced Kratom
Products that combine whole-leaf kratom with extracted alkaloids to increase potency while maintaining some whole-leaf characteristics.
Kratom Resin
A concentrated form of kratom made by boiling leaves to extract alkaloids, then evaporating the liquid to leave a resinous substance.
Kratom Shots
Small liquid servings of concentrated kratom extract, often flavored and marketed for convenience, with variable potency levels.
Fermenting Kratom
A specific processing method involving fermentation that may alter the alkaloid profile and effects of kratom products, historically sold as ‘red’ and highest incidence of microbial contamination.
Red Bubble Method
A preparation technique involving freezing kratom with lemon juice to break down plant cell walls and potentially enhance extraction.
Entourage Effect
The theory that multiple compounds in a plant work together synergistically to produce effects different from isolated compounds alone.
Alkaloid Extraction
Various methods used to separate and concentrate alkaloids from plant material, including water, alcohol, and acid-base extractions.
Supercritical CO2 Extraction
An advanced extraction method using pressurized carbon dioxide to extract compounds without chemical solvents, potentially preserving quality.
Ethanol Extraction
A common method using ethyl alcohol to extract alkaloids from plant material, often used in tincture production.
Water Extraction
Traditional extraction method using hot water to extract water-soluble compounds, similar to making tea.
Acid-Base Extraction
A chemical method that uses pH changes to selectively extract alkaloids based on their chemical properties.
Kratom Strains
Marketing terms used to categorize kratom products, often based on leaf vein color or geographic origin, though scientific evidence for distinct effects is limited.
Maeng Da
A marketing term for kratom products claimed to be particularly potent, though the designation lacks standardized meaning or verification.
Bali Kratom
A marketing designation for kratom products, though most “Bali” kratom is actually sourced from other Indonesian regions.
Thai Kratom
Products marketed as originating from Thailand, though legal restrictions in Thailand historically limited authentic Thai kratom availability.
Malaysian Kratom
Kratom products marketed as sourcing from Malaysia, one of the traditional growing regions for Mitragyna speciosa.
Indonesian Kratom
Products sourced from Indonesia, currently the largest supplier of kratom to international markets.
Medical & Health Terms
Respiratory Depression
A potentially dangerous reduction in breathing rate and depth, a major concern with traditional opioids but not observed with mitragynine in animal studies.
Minute Ventilation
The total volume of air breathed per minute, an important measure of respiratory function affected by some opioids but not significantly by mitragynine.
Tidal Volume
The amount of air inhaled and exhaled during normal, quiet breathing, which can be reduced by respiratory depressants.
Physical Dependence
The body’s adaptation to regular substance use, characterized by withdrawal symptoms when use is discontinued, distinct from addiction or substance use disorder.
Psychological Dependence
The emotional or mental reliance on a substance for normal functioning, involving craving and compulsive use patterns.
Tolerance
The need for increased amounts of a substance to achieve the same effect, which can develop with repeated use of many psychoactive substances.
Cross-Tolerance
When tolerance to one substance leads to reduced sensitivity to another related substance, relevant to kratom and opioid interactions.
Withdrawal Syndrome
Physical and psychological symptoms that occur when stopping or reducing use of a substance after physical dependence has developed.
Acute Withdrawal
The initial phase of withdrawal symptoms that occur shortly after discontinuing a substance, typically lasting days to weeks.
Post-Acute Withdrawal Syndrome (PAWS)
Extended withdrawal symptoms that can persist for weeks or months after acute withdrawal, involving mood and cognitive effects.
Substance Use Disorder (SUD)
A clinical condition characterized by impaired control over substance use despite harmful consequences, as defined in the DSM-5.
Addiction
A chronic brain disorder characterized by compulsive substance use despite adverse consequences, involving changes in brain reward and stress systems.
Craving
Intense desire or urge to use a substance, a key component of substance use disorders and an important factor in relapse risk.
Analgesia
Pain relief or the absence of pain sensation, one of the traditional uses for kratom in Southeast Asian traditional medicine.
Analgesic
A substance that provides pain relief without causing loss of consciousness, describing one of kratom’s reported therapeutic effects.
Antinociception
The reduction of pain sensitivity, measured in laboratory studies to assess the pain-relieving potential of substances like kratom alkaloids.
Hyperalgesia
Increased sensitivity to pain, which can occur as a rebound effect when certain pain medications wear off or during withdrawal.
Sedation
A calming effect that reduces activity and alertness, reported with some kratom preparations, particularly at higher doses.
Stimulation
Increased alertness and energy, traditionally reported with kratom use, particularly at lower doses and with certain preparations.
Euphoria
Feelings of well-being and happiness, which may occur with kratom use but appears less intense than with traditional opioids.
Dysphoria
Unpleasant mood states including anxiety and restlessness, which can occur during withdrawal from various substances including kratom.
Miosis
Constriction of the pupils, a common effect of opioid use that may also occur with high doses of certain kratom products.
Mydriasis
Dilation of the pupils, which can occur during withdrawal from opioids and potentially from kratom.
Constipation
Reduced bowel movement frequency, a common side effect of opioid use that may also occur with regular kratom consumption.
Nausea
Feeling of sickness in the stomach, often accompanied by urge to vomit, reported as a side effect of kratom, especially at higher doses.
Vertigo
Sensation of spinning or dizziness, occasionally reported by kratom users, particularly those new to the substance.
Hepatotoxicity
Liver damage or toxicity, rarely reported with kratom use but a concern that requires monitoring in regular users.
Seizure
Abnormal electrical activity in the brain causing convulsions, rarely reported with kratom but more common with adulterated products.
Tachycardia
Increased heart rate, occasionally reported as a side effect of kratom use, particularly with higher doses or certain individuals.
Hypertension
Elevated blood pressure, which may occur with kratom use in some individuals, requiring medical monitoring.
QT Prolongation
Changes in heart rhythm patterns that can be detected on electrocardiograms, a potential concern with some psychoactive substances.
Rhabdomyolysis
Breakdown of muscle tissue that releases proteins into the blood, rarely reported with kratom but a serious medical emergency.
Drug-Drug Interactions
When one substance affects the activity of another when both are present in the body, important for kratom users taking medications.
Cytochrome P450
A family of enzymes responsible for metabolizing many drugs and substances, including kratom alkaloids, affecting how the body processes other medications.
Biomarker
Measurable indicators of biological states or conditions, useful for monitoring safety and effects of kratom use in research studies.
Legal & Regulatory Terms
Kratom Consumer Protection Act (KCPA)
State-level legislation that regulates kratom sales while maintaining legal access, including age restrictions, labeling requirements, and alkaloid limits.
Controlled Substances Act (CSA)
Federal law that regulates the manufacture, importation, possession, use, and distribution of certain drugs, under which kratom could potentially be scheduled without increased advocacy efforts.
Schedule I Substance
The most restrictive drug classification, reserved for substances considered to have high abuse potential and no accepted medical use.
Schedule II Substance
Drugs with high abuse potential but accepted medical uses, requiring prescriptions and strict controls on manufacturing and distribution.
Emergency Scheduling
A process allowing the DEA to temporarily place substances under federal control when public safety is at immediate risk.
Substance Scheduling
The process of classifying drugs under the Controlled Substances Act based on their abuse potential, medical value, and safety profile.
Dietary Supplement
Products intended to supplement the diet, regulated under the Dietary Supplement Health and Education Act (DSHEA) of 1994.
Structure/Function Claims
Statements about how a dietary supplement affects normal body functions or structure, allowed without FDA pre-approval but requiring disclaimers.
Health Claims
Statements describing relationships between substances and disease or health conditions, requiring FDA approval for dietary supplements.
FDA Warning Letter
Official correspondence from the FDA to companies citing violations of federal law, often related to product claims or manufacturing practices.
FDA Import Alert
A directive to FDA field personnel to detain shipments of products that appear to violate FDA regulations, affecting product availability.
Enforcement Discretion
When regulatory agencies choose not to enforce certain regulations, often due to resource limitations or policy priorities.
Federal Preemption
The principle that federal law supersedes state and local laws when they conflict, relevant to kratom regulation across different jurisdictions.
Interstate Commerce
Business conducted across state lines, which falls under federal regulatory authority and affects how kratom can be regulated.
Intrastate Commerce
Business conducted within a single state, which may be subject to different regulatory requirements than interstate commerce.
Due Process
Constitutional protections requiring fair legal procedures before government can deprive individuals of rights, relevant to regulatory enforcement.
Administrative Law
The body of law governing federal and state regulatory agencies and their rulemaking processes, affecting how kratom regulations are developed.
Notice and Comment Rulemaking
The process by which agencies propose regulations and allow public input before finalizing rules, providing opportunities for stakeholder participation.
Regulatory Impact Analysis
Assessment of the costs and benefits of proposed regulations, required for significant federal rules affecting the economy.
Environmental Impact Assessment
Evaluation of potential environmental effects of regulatory actions, sometimes required for agricultural or manufacturing regulations.
Trade Regulation
Laws governing international commerce, including import/export restrictions that may affect kratom trade and availability.
Customs and Border Protection (CBP)
Federal agency responsible for enforcing import regulations and inspecting goods entering the United States, including kratom shipments.
International Narcotics Control
Global efforts to regulate controlled substances, including treaties and agreements that could affect kratom’s international status.
WHO Critical Review
Process by which the World Health Organization evaluates substances for potential international control recommendations, which kratom underwent in 2021.
Convention on Psychotropic Substances
International treaty governing the control of psychoactive drugs, under which kratom could potentially be regulated internationally.
Single Convention on Narcotic Drugs
International treaty governing narcotic drug control, the primary framework for global drug regulation.
Kratom Legality Map
Resources showing the current legal status of kratom across different states and jurisdictions, which changes as new laws are enacted.
Age Verification
Requirements for businesses to confirm customers’ ages before selling age-restricted products, included in many kratom consumer protection laws.
Good Manufacturing Practice Compliance
Adherence to established quality standards for manufacturing, often required by kratom consumer protection acts.
Statistical & Research Analysis Terms
Statistical Significance
A measure indicating that research results are unlikely to have occurred by chance, typically represented by p-values less than 0.05.
P-Value
The probability that observed results occurred by random chance alone, with lower values indicating stronger evidence against the null hypothesis.
Null Hypothesis
The assumption that there is no real difference or effect being tested, which statistical tests attempt to reject based on evidence.
Alternative Hypothesis
The research hypothesis proposing that there is a real effect or difference, tested against the null hypothesis.
Type I Error
Incorrectly rejecting a true null hypothesis (false positive), claiming an effect exists when it doesn’t, with probability set by alpha level.
Type II Error
Failing to reject a false null hypothesis (false negative), missing a real effect that actually exists, with probability called beta.
Statistical Power
The probability of correctly detecting an effect if it truly exists, related to sample size, effect size, and significance level.
Effect Size
A measure of the strength or magnitude of a relationship or difference, indicating practical significance beyond statistical significance.
Confidence Interval
A range of values that likely contains the true value of what’s being measured, indicating the precision and uncertainty of estimates.
Margin of Error
The amount of random sampling error in survey results, typically expressed as plus or minus a certain percentage.
Correlation Coefficient
A number between -1 and +1 that indicates the strength and direction of a linear relationship between two variables.
Correlation vs. Causation
Correlation indicates two variables are related, while causation means one variable directly causes changes in another – a crucial distinction in research interpretation.
Confounding Variable
A factor that influences both the independent and dependent variables, potentially creating false associations or masking true relationships.
Bias
Systematic error in research design, data collection, or analysis that leads to results that consistently differ from the truth.
Selection Bias
Error that occurs when research participants are not representative of the target population, limiting generalizability of findings.
Information Bias
Systematic error in measuring or classifying study variables, affecting the accuracy of results and conclusions.
Recall Bias
Error that occurs when participants inaccurately remember past events or exposures, common in studies asking about historical kratom use.
Observer Bias
When researchers’ expectations or knowledge influences how they collect or interpret data, potentially skewing results.
Publication Bias
The tendency for studies with positive or significant results to be published more often than those with negative or null findings.
Sample Size
The number of participants or subjects included in a research study, which affects the reliability, precision, and generalizability of results.
Power Analysis
Statistical calculation used to determine the appropriate sample size needed to detect an effect of a given magnitude with specified confidence.
Random Sampling
Method of selecting participants where each member of the population has an equal chance of being chosen, improving representativeness.
Stratified Sampling
Sampling method that divides the population into subgroups and samples from each subgroup, ensuring representation of important characteristics.
Control Group
Participants in a study who do not receive the experimental treatment, used for comparison with the treatment group to isolate treatment effects.
Treatment Group
Participants who receive the experimental intervention, whose outcomes are compared to the control group to assess treatment effects.
Baseline Characteristics
Initial measurements or attributes of study participants before any intervention, used to ensure groups are comparable and track changes.
Primary Endpoint
The main outcome measure that a study is designed to evaluate, typically the most important result for answering the research question.
Secondary Endpoint
Additional outcome measures that provide supporting information but are not the main focus of the study design.
Intention-to-Treat Analysis
Statistical approach that includes all participants in their originally assigned groups regardless of compliance, providing realistic effectiveness estimates.
Per-Protocol Analysis
Statistical approach that includes only participants who completed the study according to protocol, providing estimates of efficacy under ideal conditions.
Multivariate Analysis
Statistical methods that examine multiple variables simultaneously to understand complex relationships and control for confounding factors.
Regression Analysis
Statistical technique for examining relationships between variables and predicting outcomes based on one or more predictor variables.
Logistic Regression
Type of regression analysis used when the outcome variable is categorical, useful for studying factors associated with binary outcomes.
Cox Proportional Hazards Model
Statistical method for analyzing survival data and time-to-event outcomes, accounting for censoring and multiple predictors.
Meta-Regression
Extension of meta-analysis that examines how study characteristics relate to effect sizes across multiple studies.
Heterogeneity
Variation in effect sizes across studies in a meta-analysis, indicating whether results can be meaningfully combined.
Forest Plot
Graphical display of individual study results and overall meta-analysis results, showing effect sizes and confidence intervals.
Funnel Plot
Graph used to detect publication bias in meta-analyses by plotting effect sizes against study precision or sample size.
Understanding Research Quality
Internal Validity
The extent to which a study’s design and conduct support the conclusion that the observed relationship is causal and not due to other factors.
External Validity
The extent to which research findings can be generalized to other populations, settings, or conditions beyond the specific study circumstances.
Construct Validity
The degree to which a study’s measurements actually assess the theoretical concepts they claim to measure, ensuring meaningful interpretation.
Face Validity
The extent to which a measurement appears to assess what it claims to measure, based on superficial examination without statistical analysis.
Content Validity
The degree to which a measurement covers all aspects of the concept being studied, ensuring comprehensive assessment of the target construct.
Criterion Validity
The extent to which a measurement correlates with other established measures of the same concept, demonstrated through concurrent or predictive validity.
Concurrent Validity
The degree to which a new measurement correlates with an established measurement taken at the same time, supporting the validity of the new tool.
Predictive Validity
The ability of a measurement to predict future outcomes or behaviors, important for assessing the practical utility of research findings.
Reliability
The consistency and stability of measurements across time, observers, or measurement instruments, essential for meaningful research results.
Test-Retest Reliability
The consistency of measurements when the same test is administered to the same subjects at different time points under similar conditions.
Inter-Rater Reliability
The degree of agreement between different observers or raters measuring the same phenomenon, important for subjective assessments.
Intra-Rater Reliability
The consistency of measurements when the same observer makes repeated assessments of the same phenomenon under similar conditions.
Cronbach’s Alpha
A statistical measure of internal consistency reliability, indicating how closely related items in a scale or questionnaire are as a group.
Limitations
Factors that may affect the validity or generalizability of research findings, which responsible researchers acknowledge and discuss openly.
Conflict of Interest
Situations where researchers or institutions have financial or other interests that might influence their objectivity or interpretation of results.
Funding Source
The organization or entity that financially supports research, which may influence study design, conduct, or interpretation of results.
Reproducibility
The ability of independent researchers to obtain similar results when conducting the same study under similar conditions using the same methods.
Replicability
The ability to achieve consistent results across studies that investigate the same scientific question using similar methods.
Peer Review Process
The systematic evaluation of research by independent experts in the field before publication, ensuring quality and validity of scientific literature.
Editorial Review
Additional evaluation by journal editors beyond peer review, assessing significance, clarity, and fit with journal scope and standards.
Retraction
The formal withdrawal of published research due to serious errors, misconduct, or other issues that compromise the validity of findings.
Correction/Erratum
Published notice of errors in previously published research that require clarification but don’t invalidate the main findings.
Impact Factor
A measure of journal influence based on citation frequency, though not necessarily indicative of individual study quality or importance.
Citation Index
Database tracking how often scientific papers are cited by other researchers, indicating influence and recognition in the scientific community.
CONSORT Guidelines
International standards for reporting randomized controlled trials, ensuring complete and transparent reporting of trial methods and results.
STROBE Guidelines
Standards for reporting observational studies, promoting clear and complete reporting of study design, conduct, and findings.
PRISMA Guidelines
Standards for reporting systematic reviews and meta-analyses, ensuring comprehensive and transparent presentation of methods and results.
Toxicology & Safety Assessment Terms
Acute Toxicity
Adverse effects that occur shortly after a single exposure to a substance, typically within 24-48 hours of administration.
Chronic Toxicity
Harmful effects that develop after repeated or prolonged exposure to a substance over weeks, months, or years.
LD50 (Lethal Dose 50)
The dose of a substance that is lethal to 50% of test animals, used as a measure of acute toxicity and safety margins.
NOAEL (No Observed Adverse Effect Level)
The highest dose of a substance that produces no detectable adverse effects in test subjects, used to establish safety guidelines.
LOAEL (Lowest Observed Adverse Effect Level)
The lowest dose at which adverse effects are observed, helping to define the threshold between safe and potentially harmful exposure.
Therapeutic Index
The ratio between a toxic dose and an effective dose, indicating the safety margin of a substance for therapeutic use.
Safety Margin
The difference between doses that produce desired effects and those that cause adverse effects, indicating how safely a substance can be used.
Genotoxicity
The ability of a substance to damage DNA or chromosomes, potentially leading to mutations or cancer, assessed through specialized testing.
Mutagenicity
The capacity to cause genetic mutations, which could lead to inherited genetic changes or increased cancer risk.
Carcinogenicity
The potential to cause cancer, typically assessed through long-term animal studies and epidemiological investigations in humans.
Teratogenicity
The ability to cause birth defects or developmental abnormalities when exposure occurs during pregnancy.
Reproductive Toxicity
Adverse effects on reproductive function, fertility, or development, including effects on both male and female reproductive systems.
Developmental Toxicity
Harmful effects on the developing fetus or child, including structural abnormalities, growth retardation, or functional deficits.
Neurotoxicity
Adverse effects on the nervous system, including the brain, spinal cord, and peripheral nerves, potentially affecting cognitive or motor function.
Hepatotoxicity
Damage to the liver caused by chemical exposure, ranging from mild enzyme elevation to severe liver failure.
Nephrotoxicity
Kidney damage resulting from exposure to toxic substances, potentially affecting filtration, excretion, or other kidney functions.
Cardiotoxicity
Adverse effects on the heart or cardiovascular system, including changes in heart rhythm, blood pressure, or cardiac function.
Immunotoxicity
Harmful effects on the immune system, potentially increasing susceptibility to infections or autoimmune diseases.
Target Organ Toxicity
Specific damage to particular organs or organ systems that are most sensitive to a substance’s toxic effects.
Dose-Response Curve
Graphical representation of the relationship between dose and response, fundamental to understanding toxicity patterns and safety.
Threshold Dose
The minimum dose required to produce a detectable effect, below which no adverse effects are expected to occur.
Non-Threshold Effect
Adverse effects that theoretically can occur at any dose level, with risk increasing proportionally with dose, typical for carcinogens.
Hormesis
The phenomenon where low doses of a potentially harmful substance may actually have beneficial effects, while higher doses are harmful.
Bioaccumulation
The accumulation of substances in living organisms over time, potentially leading to higher concentrations than in the environment.
Biomonitoring
The measurement of substances or their metabolites in biological samples to assess exposure levels in individuals or populations.
Risk Assessment
Systematic evaluation of potential adverse health effects from exposure to substances, incorporating hazard identification and exposure assessment.
Hazard Identification
The process of determining whether exposure to a substance can cause adverse health effects and under what circumstances.
Exposure Assessment
Evaluation of the intensity, frequency, and duration of human contact with a substance, considering all possible routes of exposure.
Risk Characterization
Integration of hazard and exposure information to estimate the likelihood and magnitude of adverse effects in exposed populations.
Uncertainty Factor
Mathematical adjustments applied to experimental data to account for variability and uncertainties when establishing safe exposure levels.
Benchmark Dose
A dose associated with a predetermined level of response, used as an alternative to NOAEL for establishing safety standards.
Margin of Exposure
The ratio between a point of departure (like NOAEL) and estimated human exposure, indicating the safety margin for actual use.
Analytical Chemistry & Testing Terms
High-Performance Liquid Chromatography (HPLC)
Analytical technique used to separate, identify, and quantify alkaloids and other compounds in kratom samples with high precision.
Liquid Chromatography-Mass Spectrometry (LC-MS)
Advanced analytical method combining separation and identification capabilities, providing definitive identification of kratom alkaloids.
Gas Chromatography-Mass Spectrometry (GC-MS)
Analytical technique used for identifying and quantifying volatile compounds, useful for certain kratom alkaloids after derivatization.
Ultra-Performance Liquid Chromatography (UPLC)
Enhanced version of HPLC with improved resolution, speed, and sensitivity for analyzing complex kratom samples.
Tandem Mass Spectrometry (MS/MS)
Advanced mass spectrometry technique providing enhanced specificity and sensitivity for identifying and quantifying target compounds.
Nuclear Magnetic Resonance (NMR) Spectroscopy
Analytical method used to determine molecular structure and purity, particularly useful for characterizing new or unknown compounds.
Infrared (IR) Spectroscopy
Technique for identifying functional groups and molecular structure based on molecular vibrations, useful for compound identification.
Ultraviolet-Visible (UV-Vis) Spectroscopy
Method for quantifying compounds based on their absorption of ultraviolet and visible light, often used for alkaloid analysis.
Thin Layer Chromatography (TLC)
Simple separation technique used for preliminary identification and purity assessment of kratom alkaloids.
Matrix Effect
Interference from other compounds in a sample that can affect the accuracy of analytical measurements, important in complex plant extracts.
Internal Standard
A known compound added to samples to correct for variations in extraction efficiency and instrumental response during analysis.
External Standard
Reference compounds analyzed separately from samples to create calibration curves for quantitative analysis.
Calibration Curve
Graph showing the relationship between known concentrations of a standard and instrument response, used for quantifying unknowns.
Limit of Detection (LOD)
The lowest concentration of a substance that can be reliably detected but not necessarily quantified by an analytical method.
Limit of Quantification (LOQ)
The lowest concentration that can be accurately measured with acceptable precision and accuracy using a specific analytical method.
Recovery
The percentage of a known amount of substance that is successfully extracted and measured, indicating extraction efficiency.
Precision
The degree of agreement between repeated measurements of the same sample, indicating the reproducibility of an analytical method.
Accuracy
The closeness of measured values to the true or accepted value, indicating how correct an analytical method is.
Selectivity
The ability of an analytical method to distinguish the target compound from other substances that may be present in the sample.
Specificity
The ability to measure only the target compound without interference from other substances, the highest level of selectivity.
Ruggedness
The ability of an analytical method to produce consistent results under varying conditions such as different operators or instruments.
Robustness
The capacity of an analytical method to remain unaffected by small deliberate variations in method parameters.
Validation
The process of proving that an analytical method is suitable for its intended purpose and meets predetermined acceptance criteria.
Standard Operating Procedure (SOP)
Detailed written instructions for performing analytical procedures consistently and reliably across different operators and times.
Quality Control (QC) Sample
Known samples analyzed along with unknowns to monitor the performance and reliability of analytical procedures.
Blank Sample
A sample containing no target analyte, used to assess background interference and contamination in analytical procedures.
Spike Recovery
The percentage recovery of a known amount of target compound added to a sample, used to assess method accuracy.
Proficiency Testing
Evaluation of laboratory performance by analyzing samples with known values, ensuring analytical competency and reliability.
Regulatory Science & Policy Terms
Risk-Benefit Analysis
Systematic comparison of potential risks and benefits of a substance or policy to inform regulatory decisions and public health policy.
Regulatory Science
The application of scientific principles to support regulatory decision-making, bridging basic research and practical policy implementation.
Evidence-Based Policy
Policy development based on rigorous evaluation of scientific evidence rather than opinion, tradition, or political considerations alone.
Precautionary Principle
Approach to policy-making that advocates for protective action in the face of uncertainty when potential harm could be serious or irreversible.
Proportionate Response
Regulatory approach where the intensity of oversight matches the level of risk, avoiding both under-regulation and over-regulation.
Regulatory Impact Assessment
Systematic analysis of the potential economic, social, and environmental consequences of proposed regulations before implementation.
Cost-Benefit Analysis
Economic evaluation tool that compares the total costs and benefits of a policy or regulation to determine net social value.
Stakeholder Engagement
Process of involving affected parties in regulatory development, including industry, consumers, advocacy groups, and scientific experts.
Public Comment Period
Formal opportunity for stakeholders and the public to provide input on proposed regulations before they are finalized.
Notice of Proposed Rulemaking (NPRM)
Official announcement of a regulatory agency’s intention to create new rules, including rationale and opportunity for public input.
Final Rule
The completed regulation that has legal force after considering public comments and making any necessary revisions to the proposed rule.
Guidance Document
Non-binding recommendations from regulatory agencies describing their current thinking on regulatory or compliance issues.
Enforcement Priorities
Areas where regulatory agencies focus their limited enforcement resources based on risk assessment and policy objectives.
Compliance
Adherence to applicable laws, regulations, and standards, often verified through inspections, testing, and documentation review.
Regulatory Flexibility
The ability of regulations to adapt to different circumstances while maintaining essential protections and objectives.
Sunset Clause
Provision in legislation or regulation that requires periodic review and reauthorization, ensuring policies remain relevant and effective.
Grandfathering
Policy that allows existing products or practices to continue under old rules while new ones must meet updated requirements.
Safe Harbor Provision
Legal protection from liability or penalties for entities that follow specific guidelines or meet certain criteria.
Due Diligence
The level of care and investigation that a reasonable person or entity should exercise in a given situation to avoid harm.
Standard of Care
The level of attention, caution, and prudence that a reasonable person in similar circumstances would exercise.
Best Practices
Proven methods or techniques that have consistently shown superior results and are recommended as standards within an industry.
Good Governance
Principles of effective, accountable, and transparent management in both private organizations and government agencies.
Transparency
Open access to information about regulatory processes, decisions, and the data upon which they are based.
Accountability
The obligation of organizations and individuals to explain their actions and accept responsibility for their consequences.
Democratic Legitimacy
The acceptance of authority based on fair representation and participation in decision-making processes.
Scientific Integrity
Adherence to professional practices, ethical behavior, and truthfulness in the conduct and reporting of scientific research.
Conclusion
This comprehensive glossary provides the foundation for understanding the complex scientific, regulatory, and policy landscape surrounding kratom research. The terminology spans multiple disciplines including pharmacology, analytical chemistry, toxicology, clinical research, regulatory science, and public policy.
Understanding these terms enables stakeholders to:
- Critically evaluate scientific literature and research findings
- Participate meaningfully in regulatory and policy discussions
- Make informed decisions based on evidence rather than rhetoric
- Communicate effectively across disciplines and stakeholder groups
- Identify gaps in knowledge that require further research
The evolving nature of kratom research means that new terminology and concepts will continue to emerge. Staying current with scientific developments and regulatory changes requires ongoing education and engagement with peer-reviewed literature, regulatory announcements, and expert consensus statements.
For the most accurate and up-to-date information, consult:
- Peer-reviewed scientific journals
- Official regulatory agency communications
- Established scientific and medical institutions
- Professional scientific organizations and societies
This resource serves as a starting point for understanding kratom science terminology, but should be supplemented with current scientific literature and guidance from qualified healthcare professionals for personal health decisions.
Your Comprehensive Resource Library
Navigate effortlessly between General, Scientific, Legal and Regulatory and Product Safety resources— with just a single click. Join the fight against misinformation by sharing fascinating facts you discover. Simply hit ‘Download’ to receive the knowledge and invite others to explore our rich repository of information!
-
2024 Kratom Consumer Survey
This survey review offers key insights into the kratom user base, revealing who they are, why they use kratom, and their perspectives on its health effects. -
The Evolution of Kratom: A Historical Timeline
An infographic tracing kratom’s journey from its traditional origins in Southeast Asia to its current complex legal and political landscape in the United States. -
Not All Kratom Is Equal
An infographic of clear visual guide comparing the potency, history, alkaloid sources, and common product forms of leaf kratom, kratom extract, and synthetic 7. -
The Differences Between Kratom Products
A detailed diagram visual comparison of leaf kratom, extracts, and synthetic “kratom,” highlighting distinctions in their market entry, alkaloid profiles, and appropriate regulatory approaches. -
Kratom Safety, Taxonomy, and Regulation
Provides a general overview of kratom, addressing common confusion between product types and outlining the GKC’s goals for a safe and regulated marketplace.
-
2024 FDA Study: Kratom Dosing & Safety Results
A summary of an FDA-commissioned study that found controlled servings of dried leaf kratom were generally well-tolerated and resulted in no serious adverse events. -
FDA Pilot Study: Updates on Kratom Alkaloid Research
A presentation from the FDA detailing updates on its pilot dose-finding study of kratom alkaloids, including study design, preliminary observations, and next steps. -
Scientists’ Statement on 7-OH and MGPI Products
A statement from leading scientists clarifying that products with high amounts of 7-OH and MGPI are synthetic and do not constitute natural kratom. -
Scientific Statement on Kratom Products
An overview by scientists covering the history of kratom use, its current regulatory status, and the scientific understanding of its effects in the United States. -
Comprehensive Report on Substance Use Disorders
A detailed analysis comparing the prevalence, severity, and symptoms of Substance Use Disorders (SUDs) associated with kratom, caffeine, alcohol, opioids, and other substances. -
The Science of Leaf Kratom: Psychoactive Effects
This document reviews scientific evidence on leaf kratom’s effects, refuting claims about cognitive impairment and abuse potential while clarifying its atypical opioid profile. -
2024 FDA Pilot Study on Kratom Dose Response
Details of the FDA’s pilot study evaluating the effects, safety, and pharmacokinetics of orally administered botanical kratom in non-dependent, recreational polydrug users. - Show more
-
Congressional Letter to the FDA on Kratom
A letter from members of Congress to the FDA expressing concerns about mislabeled kratom products and requesting information on consumer protection measures. -
GKC Letter to FDA on Public Safety Guidance
A letter from the Global Kratom Coalition to the FDA, expressing a desire to collaborate on public safety guidance for kratom products and regulatory approaches. -
Louisiana Voter Poll on Kratom Regulation
This poll assesses public opinion in Louisiana regarding kratom’s legality and regulation, including support for banning synthetic drugs while keeping leaf kratom accessible. -
List of Banned Zip Codes: USA
A data file listing zip codes across the country where the sale, possession, or distribution of kratom is currently illegal. -
-
KCAC Position: Registration of Kratom Products
This statement advocates for a public registry of kratom vendors and products to ensure transparency, accountability, and a safer market for consumers. -
GKC Statement on Synthetic 7-OH Products
The GKC clarifies its opposition to synthetic 7-hydroxymitragynine (7-OH) products, arguing they are not kratom and should be regulated as new drugs, not supplements. -
KCAC Position: Status and Legality of 7-OH Products
This KCAC statement discusses the legal and regulatory status of 7-OH products, arguing they are not “kratom” and require a distinct regulatory approach. - Show more
-
The Severity and Prevalence of Addictive Substances
This infographic visually compares Substance Use Disorder (SUD) severity and prevalence across various substances, including kratom, heroin, alcohol, tobacco, and caffeine. -
Comparative Safety Analysis of Kratom
This document provides a comparative risk analysis of kratom versus other legal and illicit substances, using data from the FDA and poison control centers. -
Contaminants in 7-Hydroxy Mitragynine Products Report
A detailed report identifying synthetic alkaloid contaminants found in 7-Hydroxymitragynine products and discussing the serious implications for regulatory oversight and consumer safety. -
Botanical Safety Handbook: Kratom Entry
An entry for Mitragyna speciosa from the American Herbal Products Association’s handbook, providing safety classifications, contraindications, and potential drug interactions for kratom leaf. -
Debunking Myths About “7”: The Facts
A fact sheet refuting misleading claims about “7” (a synthetic substance), arguing that it is not natural kratom, is not safe, and is deceptively marketed. -
In-Depth: Debunking Myths About “7”
A more detailed version of the fact sheet refuting claims about “7,” providing comprehensive evidence that it is a dangerous, unapproved, and illegal synthetic drug. -
KCAC Position: Proper Labeling of Kratom
This statement advocates for the importance of clear, comprehensive labeling on kratom products to ensure consumer safety and outlines essential information that should be included. -
KCAC Position: Kratom Use in Children
This statement outlines concerns about kratom use by minors, highlighting potential adverse events and the issue of products being marketed in ways that appeal to children. -
UCONN Continuing Education: Kratom Course for Pharmacists
An educational program from the UCONN School of Pharmacy designed to inform pharmacists about natural kratom, its effects, and key points for patient education. -
The Fourth Wave of the Opioid Epidemic
This presentation warns of a potential “fourth wave” of the opioid crisis driven by dangerous and addictive synthetic opioid stimulators, arguing they must be banned. -
Fact Check: “Synthetic 7” and the Opioid Crisis
This KCAC statement fact-checks and refutes misleading claims that the sale of “synthetic 7” products has reduced opioid-related deaths, citing a lack of evidence. -
GKC Perfect Label – Kratom Product Label Guidelines
This document from the Global Kratom Coalition provides comprehensive guidelines for labeling kratom products to ensure consumer safety and regulatory compliance. - Show more
